GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Laboratorios Farmaceuticos Rovi SA (XMAD:ROVI) » Definitions » 5-Year Yield-on-Cost %

Laboratorios Farmaceuticos Rovi (XMAD:ROVI) 5-Year Yield-on-Cost % : 26.53 (As of May. 17, 2024)


View and export this data going back to 2007. Start your Free Trial

What is Laboratorios Farmaceuticos Rovi 5-Year Yield-on-Cost %?

Laboratorios Farmaceuticos Rovi's yield on cost for the quarter that ended in Dec. 2023 was 26.53.


The historical rank and industry rank for Laboratorios Farmaceuticos Rovi's 5-Year Yield-on-Cost % or its related term are showing as below:

XMAD:ROVI' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 5.27   Med: 19.85   Max: 57.63
Current: 26.53


During the past 13 years, Laboratorios Farmaceuticos Rovi's highest Yield on Cost was 57.63. The lowest was 5.27. And the median was 19.85.


XMAD:ROVI's 5-Year Yield-on-Cost % is ranked better than
97.35% of 151 companies
in the Biotechnology industry
Industry Median: 1.64 vs XMAD:ROVI: 26.53

Competitive Comparison of Laboratorios Farmaceuticos Rovi's 5-Year Yield-on-Cost %

For the Biotechnology subindustry, Laboratorios Farmaceuticos Rovi's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Laboratorios Farmaceuticos Rovi's 5-Year Yield-on-Cost % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Laboratorios Farmaceuticos Rovi's 5-Year Yield-on-Cost % distribution charts can be found below:

* The bar in red indicates where Laboratorios Farmaceuticos Rovi's 5-Year Yield-on-Cost % falls into.



Laboratorios Farmaceuticos Rovi 5-Year Yield-on-Cost % Calculation

Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.

Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.

Therefore, Yield-on-Cost of Laboratorios Farmaceuticos Rovi is calculated as

Yield-on-Cost=Dividend Yield %*(1+Dividend Growth Rate)^5

Laboratorios Farmaceuticos Rovi  (XMAD:ROVI) 5-Year Yield-on-Cost % Explanation

Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.


Laboratorios Farmaceuticos Rovi 5-Year Yield-on-Cost % Related Terms

Thank you for viewing the detailed overview of Laboratorios Farmaceuticos Rovi's 5-Year Yield-on-Cost % provided by GuruFocus.com. Please click on the following links to see related term pages.


Laboratorios Farmaceuticos Rovi (XMAD:ROVI) Business Description

Traded in Other Exchanges
Address
Julian Camarillo, 35, Madrid, ESP, 28037
Laboratorios Farmaceuticos Rovi SA is a biotechnology company engaged in the research, development, manufacturing, and marketing of small molecule and specialty biologic drugs. The company has a diversified portfolio of products that it markets in Spain through its specialized sales force of specialist physicians, hospitals and pharmacies. Laboratorios' research and development pipeline is focused on the expansion of applications, indications, and alternative mechanisms of action for heparin-derived products. The company aims to obtain new pharmaceutical products that enable the regular administration of formulations that are administered daily in chronic and prolonged treatments. Its two segments are Manufacturing and Marketing.

Laboratorios Farmaceuticos Rovi (XMAD:ROVI) Headlines

From GuruFocus

Rovi Corp. (ROVI) President and CEO Alfred J Amoroso sells 200,000 Shares

By GuruFocus Research GuruFocus Editor 03-19-2011

ITC Reaffirms TiVo's Second Infringement Victory

By Business Wire Business Wire 04-23-2020

Rovi Corp. (ROVI) EVP & CFO James Budge sells 29,583 Shares

By GuruFocus Research GuruFocus Editor 01-07-2011

George Soros Buys Rovi Corp

By Kyle Ferguson Kyle Ferguson 09-08-2016

Rovi Corp: Profitability in Times of Change

By Damian Illia Damian Illia 02-19-2014

Rovi Corp. (ROVI) President and CEO Alfred J Amoroso sells 33,957 Shares

By GuruFocus Research GuruFocus Editor 03-19-2011